Oncology Institute, INC 8-K filings

Starling Oncology announced robust second quarter 2026 financial results, with revenue up 34.6% and a significant improvement in Adjusted EBITDA, leading to an upward revision of full-year guidance.

The Oncology Institute, Inc. has officially rebranded to Starling Oncology, Inc., with its stock set to trade under the new ticker symbol STLN on Nasdaq.

The Oncology Institute, Inc. has successfully refinanced its existing debt with a new $75 million term loan facility from OrbiMed Opportunities (CA) V LLC, repaying its prior convertible notes.

The Oncology Institute disclosed that a third-party vendor cybersecurity incident resulted in unauthorized access to patient data.

The Oncology Institute, Inc. has prepared and furnished an investor presentation for upcoming meetings with investors.

The Oncology Institute, Inc. announced improved Q4 and full-year 2025 financial results, driven by capitated care expansion, and projects positive Adjusted EBITDA for 2026.

The Oncology Institute announced the appointment of Kim Tzoumakas, a seasoned healthcare executive, to its Board of Directors, effective February 23, 2026.

The Oncology Institute, Inc. reaffirmed its 2025 financial guidance and provided a preliminary 2026 outlook, projecting its first full year of Adjusted EBITDA profitability as a public company.

The Oncology Institute, Inc. announced the appointment of Mark D. Stolper, current CFO of RadNet, Inc., to its Board of Directors, effective January 2, 2026.

The Oncology Institute announced the resignation of board member Gabe Ling, effective December 1, 2025, with no disagreements cited.

The Oncology Institute, Inc. presented an investor update highlighting 20%+ revenue growth in 2025 and a path to EBITDA positive by Q4 2025, alongside strategic capital raises.

The Oncology Institute, Inc. reported strong third-quarter 2025 financial results, driven by robust fee-for-service and pharmacy growth, leading to an increase in its full-year 2025 revenue and Adjusted EBITDA guidance.

The Oncology Institute, Inc. disclosed a cybersecurity incident affecting a software provider, expecting a brief, immaterial delay in fee-for-service collections.

The Oncology Institute, Inc. announced Richard Barasch's retirement from the Board, with Anne McGeorge succeeding him as Chair, effective August 12, 2025.

The Oncology Institute, Inc. reported strong second quarter 2025 financial results, driven by significant revenue growth and reaffirmed its full-year 2025 guidance.

The Oncology Institute is exploring a potential private placement of securities (PIPE Financing) to fuel its growth strategy in the oncology market.

The Oncology Institute (TOI) announced its Q1 2025 financial results, showcasing revenue growth and reaffirming its full-year 2025 guidance.

The Oncology Institute's annual meeting saw stockholders elect directors, ratify the appointment of BDO USA, LLP as the company's accountant, and approve a potential reverse stock split.

Jeremy Castle, Chief Operating Officer of The Oncology Institute, Inc., has resigned, effective May 30, 2025.

The Oncology Institute, Inc. has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing.

The Oncology Institute finalized a private placement of common stock and warrants, along with an exchange of convertible notes for preferred stock and warrants, to bolster its financial position.

The Oncology Institute (TOI) has announced a private placement expected to generate $16.5 million in gross proceeds to support organic growth and working capital.

The Oncology Institute is considering a private placement of securities (PIPE Financing) to support its growth strategy, focusing on value-based contracts and leveraging its existing clinical capacity.

The Oncology Institute (TOI) announced its Q4 and full year 2024 financial results, highlighting revenue growth and improved operational efficiency, while also providing financial guidance for 2025.

The Oncology Institute (TOI) announces an amendment to its facility agreement with Deerfield Management, including a $20 million debt paydown and the removal of a minimum cash covenant.

The Oncology Institute has been granted a second extension until June 16, 2025, to regain compliance with Nasdaq's minimum bid price requirement.

The Oncology Institute (TOI) announced a 21.8% increase in revenue for the third quarter of 2024, driven by strong dispensary performance, while also reporting a decrease in gross profit and an adjusted EBITDA loss.

The Oncology Institute reports the resignation of director Maeve OMeara, effective January 1, 2025, and the change of status of Gabriel Ling to an independent director on the same date.

The Oncology Institute has announced the resignation of its CFO, Mihir Shah, effective October 14, 2024, and the subsequent promotion of Robert Carter to the role.

The Oncology Institute reported a 22.9% increase in revenue for the second quarter of 2024, but experienced a decrease in gross profit and updated its full-year guidance.